XML 17 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover - shares
 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Document Information [Line Items]    
Document Type 20-F  
Amendment Flag false  
Document Period End Date Jun. 30, 2023  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus FY  
Entity Registrant Name Kazia Therapeutics Limited  
Entity Central Index Key 0001075880  
Current Fiscal Year End Date --06-30  
Entity Well-known Seasoned Issuer No  
Entity Current Reporting Status Yes  
Entity Filer Category Non-accelerated Filer  
Entity Emerging Growth Company false  
Entity Voluntary Filers No  
Entity Shell Company false  
Entity Interactive Data Current Yes  
Document Transition Report false  
Document Annual Report true  
Document Shell Company Report false  
Entity Address, Address Line One Three International Towers Level 24, 300 Barangaroo Avenue  
Entity Address, City or Town Sydney  
Entity Address, Postal Zip Code 2000  
Entity Address Country AU  
Document Registration Statement false  
Document Accounting Standard International Financial Reporting Standards  
Entity Common Stock, Shares Outstanding 228,029,114  
Entity Incorporation, State or Country Code C3  
Entity File Number 0-29962  
Title of 12(b) Security American Depositary Shares, each representing tenOrdinary Shares*  
Trading Symbol KZIA  
Security Exchange Name NASDAQ  
ICFR Auditor Attestation Flag false  
Auditor Name BDO Audit Pty Ltd GRANT THORNTON AUDIT PTY LTD
Auditor Firm ID 2256 2233
Auditor Location Sydney, Australia Sydney, Australia
Business Contact [Member]    
Document Information [Line Items]    
Contact Personnel Name Karen Krumeich  
Contact Personnel Email Address Karen.Krumeich@kaziatherapeutics.com  
Entity Address, Address Line One Three International Towers Level 24, 300 Barangaroo Avenue  
Entity Address, City or Town Sydney  
Entity Address, Postal Zip Code 2000  
Entity Address Country AU  
Country Region 61  
City Area Code 2  
Local Phone Number 9472-4101